Chronic treatment with the opioid antagonist drug, naltrexone, increases opioid binding sites in the central nervous system of rats and produces a 50% increase in the antinociceptive (analgesic) action of morphine (supersensitivity). In the mouse, naltrexone treatment produces a 3-fold greater increase in the analgesic potency of morphine than in the rat. While the increase in binding and morphine analgesia is a regularly observed phenomenon, little is known about the pharmacodynamics of opioid antagonist-induced upregulation and supersensitivity. The purpose of this application is to examine the consequences of chronic naltrexone-treatment upon opioid and nonopioid pharmacodynamics and brain opioid binding. We will determine the optimal dose of naltrexone to produce supersensitivity in the rat and mouse, and use this information to examine the development of tolerance and dependence to opioid agonists. The effect of naltrexone treatment on the development of supersensitivity and brain opioid binding in morphine-sensitive and insensitive strains of mice will be determined. In order to examine the role of particular opioid receptors in supersensitivity, the effect of selective opioid agonists will be determined. Since it is not known if supersensitivity is mediated by populations of neurons in the brain or spinal cord, or both, the contribution of these sites will be studied. The potential alterations in psychopharmacologic and toxic response to opioid and nonopioid drugs following opioid antagonist treatment will also be examined as will the possible pharmacokinetic changes in opioid agonists in brain and biofluids following naltrexone treatment. The effects of naltrexone-treatment on stress-induced (cold water swim) analgesia in the rat will be evaluated to assess the contribution of opioid and nonopioid systems in stress. Given that naltrexone has been recently approved for chronic use in the treatment of opioid dependence, these questions are of particular interest, since the possible consequences of upregulation in humans are unknown. Studies outlined in this proposal will systematically examine the functional consequences of opioid antagonist treatment on a variety of opioid and nonopioid effects. These studies will allow us to evaluate the significance, generality and specificity of opioid antagonist-induced upregulation and supersensitivity.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004185-03
Application #
3209460
Study Section
(DABA)
Project Start
1987-09-01
Project End
1989-08-31
Budget Start
1988-09-01
Budget End
1989-08-31
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
St. John's University
Department
Type
Schools of Pharmacy
DUNS #
City
Queens
State
NY
Country
United States
Zip Code
11439
Duttaroy, A; Shen, J; Shah, S et al. (1999) Opioid receptor upregulation in mu-opioid receptor deficient CXBK and outbred Swiss Webster mice. Life Sci 65:113-23
Duttaroy, A; Gregorio, G; Shah, S et al. (1998) Acute ethanol exposure decreases the analgesic potency of morphine in mice. Life Sci 62:PL35-41
Shen, J; Shah, S; Hsu, H et al. (1998) The effects of antisense to Gialpha2 on opioid agonist potency and Gialpha2 protein and mRNA abundance in the mouse. Brain Res Mol Brain Res 59:247-55
Shah, S; Duttaroy, A; Sehba, F et al. (1997) The effect of ethanol drinking on opioid analgesia and receptors in mice. Alcohol 14:361-6
Shen, J; Chan, K W; Chen, B T et al. (1997) The effect of in vivo ethanol consumption on cyclic AMP and delta-opioid receptors in mouse striatum. Brain Res 770:65-71
Shah, S; Breivogel, C; Selly, D et al. (1997) Time-dependent effects of in vivo pertussis toxin on morphine analgesia and G-proteins in mice. Pharmacol Biochem Behav 56:465-9
Shah, S; Duttaroy, A; Chen, B T et al. (1997) The effect of mu-opioid receptor antisense on morphine potency and antagonist-induced supersensitivity and receptor upregulation. Brain Res Bull 42:479-84
Sehba, F; Duttaroy, A; Shah, S et al. (1997) In vivo homologous regulation of mu-opioid receptor gene expression in the mouse. Eur J Pharmacol 339:33-41
Duttaroy, A; Kirtman, R; Farrell, F et al. (1997) The effect of cumulative dosing on the analgesic potency of morphine in mice. Pharmacol Biochem Behav 58:67-71
Yoburn, B C; Shah, S; Chan, K et al. (1995) Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity. Pharmacol Biochem Behav 51:535-9

Showing the most recent 10 out of 35 publications